Bluejay Diagnostics reported Q2 2026 results, highlighting the completion of targeted enrollment for its SYMON-II pivotal clinical study involving 750 patients and the advancement toward an FDA 510(k) submission. The company strengthened its balance sheet with approximately $9.6 million in cash at June 30, 2026, up from $5.2 million at year-end 2025, following a private placement in June that generated roughly $7.6 million in net proceeds. Management stated these resources are sufficient to fund operations through the second quarter of 2027 and noted the signing of a US manufacturing contract to mitigate supply-chain risks for its Symphony IL-6 test. Bluejay Diagnostics is a medical diagnostics company focused on developing rapid, near-patient testing systems for sepsis triage and monitoring.
